Advanced Oncotherapy #AVO – Exclusive distribution agreement for China and other geographies & new equity investments for a total consideration of £37m

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has signed an exclusive distribution agreement with Yantai CIPU Medical Technology Co. Ltd. to market and sell Advanced Oncotherapy’s LIGHT system across China, Macau, Taiwan, Hong-Kong and South Korea. Under the agreement, Yantai CIPU will make a payment of £16.5 […]

Advanced Oncotherapy (AVO) – Non-Exec Dr Nick Plowman invests GBP250,000 at 30p per share

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Dr Nick Plowman, Non-Executive Director, will invest £250,000 in the Company. The investment will be satisfied through the issue of 833,333 new ordinary shares of 25 pence nominal value in the capital of the Company at a price of […]

Advanced Oncotherapy (AVO) – Additional financing agreement

Advanced Oncotherapy plc (AIM: AVO), the developer of next generation proton therapy systems for cancer treatment, announces that on Tuesday 25 April it drew down a further £2 million as part of the 12-month convertible and redeemable loan agreement announced on 27 March 2017 with Blackfinch Investment Ltd, through its subsidiary Henslow Trading Limited. This […]

Advanced Oncotherapy (AVO) strengthens its board – Daily Telegraph

From Daily Telegraph – StockMarket Wire Advanced Oncotherapy has appointed Dr Nick Plowman as a non-executive director with immediate effect. Plowman is senior clinical oncologist at St Bartholomew’s Hospital and the Hospital for Sick Children at Great Ormond Street in London. Executive chairman Michael Sinclair said: “Dr Plowman has been a welcome source of expert […]

Advanced Oncotherapy (AVO) – Appoints Dr Nick Plowman as Non-Executive Director

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces the appointment of Dr Nick Plowman, Senior Clinical Oncologist at St Bartholomew’s Hospital (“Barts”) and the Hospital for Sick Children at Great Ormond Street (“GOSH”) in London, as a Non-Executive Director with immediate effect. Dr Nick Plowman is the UK’s […]

Advanced Oncotherapy (AVO) – Significant Shareholder

Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it was informed on 7 February 2017 that Dr Nick Plowman, Chairman of the Company’s medical advisory board, became a significant shareholder on 6 June 2016 and, following subsequent share purchases, currently holds 2,636,799 ordinary shares of 25 pence each in […]